Latest Sipuleucel-T Stories
DURHAM, N.C., Oct.
NEW YORK, Oct.
SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, November 3, 2010 at 4:30 p.m. ET to review third quarter financial results.
SEATTLE and WASHINGTON, Oct. 1 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGEÂ® (sipuleucel-T) data presentations taking place at the 25th International Society for Biological Therapy of Cancer (iSBTc) annual meeting in Washington, D.C.
BURLINGTON, Mass., Sept.
DETROIT, Sept. 15 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Center in Detroit was recently selected to be one of 50 sites in the United States to offer the new U.S.
SEATTLE, Sept. 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Ian Clark, chief executive officer and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group, has resigned from the company's Board of Directors.
LOS ANGELES, Sept. 13 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) with a twelve month target price of $4.40.
- A trick or prank.